Dr. Ulrich Granzer
Granzer Regulatory Consulting & Services
Ulrich Granzer, Ph.D., the founder of Granzer Regulatory Consulting & Services, graduated as a pharmacist in 1984 from the University of Marburg. He then persued his Ph.D. studies, during which he also acted as a lecturer in pharmaceutical chemistry. In 1988, he served in the German Air Force and advanced to the rank of a captain with responsibility for drug safety. In 1989, Dr. Granzer started his industry career in the Regulatory Affairs department at Glaxo. In 1993, he was appointed Director of Regulatory Affairs. He then served as a member of Glaxo Wellcome's Global Regulatory Board.
In 1998, Dr. Granzer joined BASF Pharma as Vice President of Global Regulatory Center, assuming global responsibility for Regulatory Affairs, Drug Safety, and GXP in drug development.
At Knoll, he was responsible for the development of small molecules as well as several biological compounds in the indications of stroke, septic shock, and rheumatoid arthritis. He was instrumental in the program for the first fully human anti-TNF antibody, now marketed as Humira.
After Knoll was been taken over by Abbott, Dr. Granzer joined Bayer as Vice President, Global Regulatory Affairs with responsibility for all regulatory aspects of development and submission projects worldwide.
In 2002, he founded his own company: Granzer Regulatory Consulting & Services.
